Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Dec 1;113(11):3242-7.
doi: 10.1002/cncr.23929.

Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Stephen Qualman  1 , James Lynch, Julia Bridge, David Parham, Lisa Teot, William Meyer, Alberto Pappo
Affiliations

Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Stephen Qualman et al. Cancer. .

Erratum in

  • Cancer. 2009 Jun 15;115(12):2806

Abstract

Background: Anapalsia is rare in childhood rhabdomyosarcoma and has not been included in the International Classification of Rhabdomyosarcoma (ICR). A recent review of cases from the Soft Tissue Sarcoma Committee of the Children's Oncology Group (COG) suggests that anaplasia might be more common than previously reported and may impact clinical outcome.

Methods: The prevalence of anaplasia (focal or diffuse) was prospectively assessed in 546 eligible cases who were registered in an Intergroup Rhabdomyosarcoma Study Group (IRSG) or COG therapeutic trial from 1995 through 1998. The incidence of anaplasia in tumor samples and its impact in predicting clinical outcome was assessed.

Results: Overall, 71 (13%) of all samples analyzed had anaplasia. Anaplasia was more common in patients with tumors in favorable sites and was less commonly observed in younger patients and in those with stage II, III, or clinical group III disease. Regardless of its distribution (focal or diffuse), on univariate analysis the presence of anaplasia negatively influenced the failure-free survival rate (63% vs 77% at 5 years) and overall survival (68% vs 82% at 5 years) rates in patients with embryonal rhabdomyosarcoma. This effect was most pronounced in children with intermediate-risk tumors. Anaplasia did not affect outcome in patients with alveolar tumors.

Conclusions: The incidence of anaplasia in patients with rhabdomyosarcoma is higher than previously described and may be of prognostic significance in children with intermediate-risk embryonal rhabdomyosarcoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Figure 1A and 1B. A The tumor cells possess enlarged, hyperchromatic, irregular nuclei and aberrant mitotic figures, representative of anaplasia. B Rhabdomyosarcoma with diffuse anaplasia, containing confluent sheets of anaplastic tumor cells.
Figure 2
Figure 2. FFS in patients with intermediate risk embryonal rhabdomyosarcoma
Figure 3
Figure 3. Survival in patients with intermediate risk embryonal rhabdomyosarcoma
See this image and copyright information in PMC

References

    1. Ries L, Smith M, Gurney J, et al. Bethesda, MD: National Cancer Institute; 1999. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1995. SEER program Pub No 99–4649.
    1. Qualman SJ, Bowen J, Parham DM, et al. Protocol for the examination of specimens from patients (children and young adults) with rhabdomyosarcoma. Arch Pathol Lab Med. 2003;127:1290–1297. - PubMed
    1. Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol. 2001;23:215–220. - PubMed
    1. Qualman SJ, Coffin CM, Newton WA, et al. Intergroup Rhabdomyosarcoma Study: update for pathologists. Pediatr Dev Pathol. 1998;1:550–561. - PubMed
    1. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J.Clin.Oncol. 2001;19:3091–3102. - PubMed

Publication types